TERUMO BLOOD & CELL THERAPIES CORPORATE SESSION Improve Your Starting Material and the Patient Experience with Data and Partnering
Friday, June 2, 2023 08:00 AM - 09:00 AM
Salle Maillot
Corporate Session
Improve Your Starting Material and the Patient Experience with Data and Partnering
Chair
Dalip Sethi, PhD, Director Scientific Affairs, Terumo Blood and Cell Technologies, Global
Speakers
John Manis, MD, Boston Children’s Hospital and Harvard Medical School Teaching Hospital, USA
David Collin, Senior Director of Clinical Operations for Cell & Gene Therapy, Quell Therapeutics, UK
Sinju Thomas, Lead Apheresis Nurse Practitioner, Collection Facility Director for Apheresis Imperial College Healthcare NHS Trust, UK
Elizabeth (Liz) Valdez, RN, MSN, Terumo Blood and Cell Technologies, USA
A patient-first discussion among thought leaders about how the industry can influence the quality of their starting material and why this is important in the delivery and development of cell and gene therapies.
Chair
Dalip Sethi, PhD, Director Scientific Affairs, Terumo Blood and Cell Technologies, Global
Speakers
John Manis, MD, Boston Children’s Hospital and Harvard Medical School Teaching Hospital, USA
David Collin, Senior Director of Clinical Operations for Cell & Gene Therapy, Quell Therapeutics, UK
Sinju Thomas, Lead Apheresis Nurse Practitioner, Collection Facility Director for Apheresis Imperial College Healthcare NHS Trust, UK
Elizabeth (Liz) Valdez, RN, MSN, Terumo Blood and Cell Technologies, USA
A patient-first discussion among thought leaders about how the industry can influence the quality of their starting material and why this is important in the delivery and development of cell and gene therapies.
David Collin
Senior Director of Clinical Operations for Cell & Gene Therapy
Quell Therapeutics
Speaker
Senior Director of Clinical Operations for Cell & Gene Therapy
Quell Therapeutics
Speaker